Drug
Ibutamoren clinical trials
Also written LUM-201 and MK-0677.
- studies test it
- 13
- open now
- 4
- in phase 3
- 2
- first study started
- 1998
Keep track of what changes. Save the ibutamoren studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2022 (2); 2 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 10
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Lumos Pharma (7) · University of Virginia (3) · Merck Sharp & Dohme LLC (2) · Massachusetts General Hospital (1)
Studies
Open first, then newest update. How each study uses ibutamoren is read from its arms, and is right about nine times in ten.
Testing it · 13
- Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyRecruitingPhase 3Lumos PharmaNCT06948214Written as LUM-201
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsNot yet recruitingPhase 2Lumos PharmaNCT07754045Written as LUM-201
- Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone DeficiencyNot yet recruitingPhase 3Lumos PharmaNCT07129759Written as LUM-201
- A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)Enrolling by invitationPhase 2Lumos PharmaNCT05796440Written as LUM-201
- Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)CompletedPhase 2Lumos PharmaNCT04614337Written as LUM-201
- Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)CompletedPhase 2Lumos PharmaNCT05250063Written as LUM-201
- The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseCompletedPhase 2Massachusetts General HospitalNCT05364684Written as LUM-201
- PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)Active, not recruitingPhase 2Lumos PharmaNCT04806854Written as LUM-201
- Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsWithdrawnPhase 2University of VirginiaNCT01343641Written as MK-0677
- Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD PatientsCompletedNot applicableUniversity of VirginiaNCT00395291Written as MK-0677
- Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)TerminatedPhase 2Merck Sharp & Dohme LLCNCT00128115Written as MK0677
- Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)CompletedPhase 2Merck Sharp & Dohme LLCNCT00074529Written as MK0677
- Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older AdultsCompletedPhase 1/2University of VirginiaNCT00474279Written as Orally active growth hormone secretagogue (MK-677)
Codes
What other systems call ibutamoren · ClinicalTrials.gg INT003860
- MeSH (NLM) C094817ibutamoren mesylateOne source NLM
- UNII (FDA) GJ0EGN38ULIBUTAMORENConfirmed FDA, NLM, Wikidata
- RxNorm 1805438Confirmed FDA, Wikidata
- Wikidata Q5984942ibutamorenConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97488IbutamorenConfirmed FDA, Wikidata
- DrugBank DB18214One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C094817 | ibutamoren mesylate | One source NLM |
| UNII (FDA) | GJ0EGN38UL | IBUTAMOREN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1805438 | — | Confirmed FDA, Wikidata |
| Wikidata | Q5984942 | ibutamoren | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97488 | Ibutamoren | Confirmed FDA, Wikidata |
| DrugBank | DB18214 | — | One source Wikidata |
Also registered as ibutamoren mesylate (UNII R90JB6QJ2B · RxNorm 1805437).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.